BRAF and central nervous system cancer: Whilst some countries are already using BRAF/MEK inhibitors upfront and off-label, as mentioned before, the validity of this approach is currently being tested within a clinical trial (NCT05566795) (DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) - Full Text View - ClinicalTrials.Gov, n.d.)(39, 40).